Results 11 to 20 of about 7,827 (211)

Research progress on the clinical application of esketamine [PDF]

open access: yesZhongguo linchuang yanjiu
Esketamine is the S-enantiomer of racemic ketamine, which has a similar pharmacological mechanism to ketamine. Esketamine has the advantages of fast onset, fast metabolism, little impact on circulatory and respiratory functions, and strong sedative and ...
JIANG Lele, DU Xiaoxuan
doaj   +2 more sources

Case report: two cases of rhabdomyolysis following esketamine treatment [PDF]

open access: yesFrontiers in Psychiatry
Major depressive disorder is a mental disorder affecting millions of people worldwide. A considerable proportion of patients demonstrate a lack of response to conventional treatment.
René Zeiss   +3 more
doaj   +3 more sources

Sub-anesthetic dose of esketamine decreases postoperative opioid self-administration after spine surgery: a retrospective cohort analysis

open access: yesScientific Reports
The use of intraoperative sub-anesthetic esketamine for postoperative analgesia is controversial. In this study, the impact of sub-anesthetic esketamine on postoperative opioid self-administration was determined.
Hongyu Zheng   +5 more
doaj   +2 more sources

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment [PDF]

open access: yesEuropean Journal of Pharmacology
Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression.
Jolien K.E. Veraart   +4 more
openaire   +4 more sources

Efficacy of Intravenous Administration of Esketamine in Preventing and Treating Rebound Pain After Thoracic Paravertebral Nerve Block: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial

open access: yesDrug Design, Development and Therapy
Xu Zeng,1,2 Xianjie Zhang,2 Wencai Jiang,2,* Xinyu Zhou1,* 1Department of Anaesthesiology, Chengdu Medical College, Chengdu, People’s Republic of China; 2Department of Anesthesiology, People’s Hospital of Deyang City, Deyang, People’s Republic of
Zeng X, Zhang X, Jiang W, Zhou X
doaj   +1 more source

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

open access: yesEuropean Psychiatry, 2021
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly
C. Gastaldon   +3 more
doaj   +1 more source

Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries

open access: yesMiddle East Current Psychiatry, 2023
Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed   +5 more
doaj   +1 more source

ED90 of epidural esketamine with 0.075% ropivacaine for labor analgesia in nulliparous parturients: a prospective, randomized and dose-finding study

open access: yesFrontiers in Pharmacology, 2023
Background: Because it has been reported that racemic ketamine had a local anesthetic-sparing effect when used for epidural analgesia this would suggest the likelihood of a potential advantage (less pruritus) over opioid drugs.
Siwen Lou   +5 more
doaj   +1 more source

Potential ‘anti-cancer’ effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells

open access: yesEuropean Journal of Medical Research, 2023
Background Esketamine, an N-methyl-D-aspartate receptor antagonist, is commonly used for anesthesia and analgesia clinically. It was reported to negatively regulate cell proliferation, metastasis and apoptosis in cancer cells, including lung cancer and ...
Chao Li   +3 more
doaj   +1 more source

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode

open access: yesEuropean Psychiatry, 2023
Introduction Major depressive disorder is one of the most common and disabling mental disorders. More than 30% of individuals do not achieve remission after several trials of antidepressants and treatment-resistant depression (TRD) is associated with ...
M. D. R. D. R. F. D. A. Basto   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy